Literature DB >> 29791798

Non-Natural Linker Configuration in 2,6-Dipeptidyl-Anthraquinones Enhances the Inhibition of TAR RNA Binding/Annealing Activities by HIV-1 NC and Tat Proteins.

Alice Sosic1, Irene Saccone2, Caterina Carraro1, Thomas Kenderdine3, Elia Gamba1, Giuseppe Caliendo2, Angela Corvino2, Paola Di Vaio2, Ferdinando Fiorino2, Elisa Magli2, Elisa Perissutti2, Vincenzo Santagada2, Beatrice Severino2, Valentina Spada2, Dan Fabris3, Francesco Frecentese2, Barbara Gatto1.   

Abstract

The HIV-1 nucleocapsid (NC) protein represents an excellent molecular target for the development of anti-retrovirals by virtue of its well-characterized chaperone activities, which play pivotal roles in essential steps of the viral life cycle. Our ongoing search for candidates able to impair NC binding/annealing activities led to the identification of peptidyl-anthraquinones as a promising class of nucleic acid ligands. Seeking to elucidate the inhibition determinants and increase the potency of this class of compounds, we have now explored the effects of chirality in the linker connecting the planar nucleus to the basic side chains. We show here that the non-natural linker configuration imparted unexpected TAR RNA targeting properties to the 2,6-peptidyl-anthraquinones and significantly enhanced their potency. Even if the new compounds were able to interact directly with the NC protein, they manifested a consistently higher affinity for the TAR RNA substrate and their TAR-binding properties mirrored their ability to interfere with NC-TAR interactions. Based on these findings, we propose that the viral Tat protein, sharing the same RNA substrate but acting in distinct phases of the viral life cycle, constitutes an additional druggable target for this class of peptidyl-anthraquinones. The inhibition of Tat-TAR interaction for the test compounds correlated again with their TAR-binding properties, while simultaneously failing to demonstrate any direct Tat-binding capabilities. These considerations highlighted the importance of TAR RNA in the elucidation of their inhibition mechanism, rather than direct protein inhibition. We have therefore identified anti-TAR compounds with dual in vitro inhibitory activity on different viral proteins, demonstrating that it is possible to develop multitarget compounds capable of interfering with processes mediated by the interactions of this essential RNA domain of HIV-1 genome with NC and Tat proteins.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29791798      PMCID: PMC7175782          DOI: 10.1021/acs.bioconjchem.8b00104

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  48 in total

Review 1.  Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA.

Authors:  T M Rana; K T Jeang
Journal:  Arch Biochem Biophys       Date:  1999-05-15       Impact factor: 4.013

2.  Fragments of the HIV-1 Tat protein specifically bind TAR RNA.

Authors:  K M Weeks; C Ampe; S C Schultz; T A Steitz; D M Crothers
Journal:  Science       Date:  1990-09-14       Impact factor: 47.728

3.  Simultaneous recognition of HIV-1 TAR RNA bulge and loop sequences by cyclic peptide mimics of Tat protein.

Authors:  Amy Davidson; Thomas C Leeper; Zafiria Athanassiou; Krystyna Patora-Komisarska; Jonathan Karn; John A Robinson; Gabriele Varani
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-07       Impact factor: 11.205

4.  Linker dependent intercalation of bisbenzimidazole-aminosugars in an RNA duplex; selectivity in RNA vs. DNA binding.

Authors:  Nihar Ranjan; Dev P Arya
Journal:  Bioorg Med Chem Lett       Date:  2016-10-27       Impact factor: 2.823

5.  High affinity binding of TAR RNA by the human immunodeficiency virus type-1 tat protein requires base-pairs in the RNA stem and amino acid residues flanking the basic region.

Authors:  M J Churcher; C Lamont; F Hamy; C Dingwall; S M Green; A D Lowe; J G Butler; M J Gait; J Karn
Journal:  J Mol Biol       Date:  1993-03-05       Impact factor: 5.469

6.  Noncovalent probes for the investigation of structure and dynamics of protein-nucleic acid assemblies: the case of NC-mediated dimerization of genomic RNA in HIV-1.

Authors:  Kevin B Turner; Andrew S Kohlway; Nathan A Hagan; Daniele Fabris
Journal:  Biopolymers       Date:  2009-04       Impact factor: 2.505

7.  Arginine-linked neomycin B dimers: synthesis, rRNA binding, and resistance enzyme activity.

Authors:  Yi Jin; Derrick Watkins; Natalya N Degtyareva; Keith D Green; Meredith N Spano; Sylvie Garneau-Tsodikova; Dev P Arya
Journal:  Medchemcomm       Date:  2015-10-03       Impact factor: 3.597

8.  Multivalency in the recognition and antagonism of a HIV TAR RNA-TAT assembly using an aminoglycoside benzimidazole scaffold.

Authors:  Sunil Kumar; Nihar Ranjan; Patrick Kellish; Changjun Gong; Derrick Watkins; Dev P Arya
Journal:  Org Biomol Chem       Date:  2016-02-14       Impact factor: 3.876

9.  Structural determinants of TAR RNA-DNA annealing in the absence and presence of HIV-1 nucleocapsid protein.

Authors:  Igor Kanevsky; Françoise Chaminade; Yingying Chen; Julien Godet; Brigitte René; Jean-Luc Darlix; Yves Mély; Olivier Mauffret; Philippe Fossé
Journal:  Nucleic Acids Res       Date:  2011-06-30       Impact factor: 16.971

10.  Dynamic interactions of the HIV-1 Tat with nucleic acids are critical for Tat activity in reverse transcription.

Authors:  Christian Boudier; Nicolas Humbert; Françoise Chaminade; Yingying Chen; Hugues de Rocquigny; Julien Godet; Olivier Mauffret; Philippe Fossé; Yves Mély
Journal:  Nucleic Acids Res       Date:  2013-10-22       Impact factor: 16.971

View more
  4 in total

1.  Multiple in Vitro Inhibition of HIV-1 Proteins by 2,6-Dipeptidyl-anthraquinone Conjugates Targeting the PBS RNA.

Authors:  Elia Gamba; Alice Sosic; Irene Saccone; Elisa Magli; Francesco Frecentese; Barbara Gatto
Journal:  ACS Med Chem Lett       Date:  2020-03-23       Impact factor: 4.345

2.  HIV-1 Nucleocapsid Protein Unfolds Stable RNA G-Quadruplexes in the Viral Genome and Is Inhibited by G-Quadruplex Ligands.

Authors:  Elena Butovskaya; Paola Soldà; Matteo Scalabrin; Matteo Nadai; Sara N Richter
Journal:  ACS Infect Dis       Date:  2019-11-06       Impact factor: 5.084

3.  Bis-3-Chloropiperidines Targeting TAR RNA as A Novel Strategy to Impair the HIV-1 Nucleocapsid Protein.

Authors:  Alice Sosic; Giulia Olivato; Caterina Carraro; Richard Göttlich; Dan Fabris; Barbara Gatto
Journal:  Molecules       Date:  2021-03-26       Impact factor: 4.411

4.  In Vitro Evaluation of Bis-3-Chloropiperidines as RNA Modulators Targeting TAR and TAR-Protein Interaction.

Authors:  Alice Sosic; Giulia Olivato; Caterina Carraro; Richard Göttlich; Dan Fabris; Barbara Gatto
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.